新型冠狀病毒肺炎（COVID-19）在全球蔓延，引起世界各國(guó)高度關(guān)注。其傳染性強(qiáng)、危害大，目前尚無(wú)確切有效的抗病毒藥物。國(guó)家衛(wèi)生健康委員會(huì)發(fā)布了《新型冠狀病毒肺炎診療方案（試行第七版）》，其中首次提出了托珠單抗免疫治療方案。檢索國(guó)內(nèi)外托珠單抗治療免疫系統(tǒng)疾病的論文，分析托珠單抗用于治療COVID-19重癥和危重癥的有效性，并從安全性角度出發(fā)，介紹診療方案的藥物相互作用、特殊人群用藥、不良反應(yīng)及用藥注意事項(xiàng)，可為COVID-19重型及危重型患者的治療提供用藥參考。

Since December 2019, COVID-19 had spread many countries, attracting high attention from the world. Its infectivity is strong, harm is big, at present there is no definite effective antiviral drug. Recently, the national health commission released the latest "new coronavirus pneumonia diagnosis and treatment program (trial seventh edition)", which for the first time proposed immunotherapy program based on Tocilizumab (TCZ). In this paper, firstly, a review of articles on the treatment of immune system diseases with TCZ at home and abroad was conducted to analyze the effectiveness of TCZ in the treatment of severe and critical COVID-19. Then, from the safety point of view, the drug interactions, drug use in special population, adverse reactions and medication precautions were presented in detail, which can be used as a medication reference for the treatment of COVID-19 severe and critical patients.

湖北省衛(wèi)生健康委員會(huì)（WJ2019F170）